Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma

CONTEXT: Aggressive pituitary tumors that have progressed following temozolomide have limited treatment options. Peptide receptor radionuclide therapy and immunotherapy may have a complementary role in the management of these tumors. METHODS: We provide follow-up data on a previously reported patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Andrew L, Tabar, Viviane, Young, Robert J, Cohen, Marc, Cuaron, John, Yang, T Jonathan, Rosenblum, Marc, Rudneva, Vasilisa A, Geer, Eliza B, Bodei, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402930/
https://www.ncbi.nlm.nih.gov/pubmed/34466766
http://dx.doi.org/10.1210/jendso/bvab133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402930/
https://www.ncbi.nlm.nih.gov/pubmed/34466766
http://dx.doi.org/10.1210/jendso/bvab133

Ejemplares similares